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Our purpose was to characterize changes in paraoxonase 1 (PON1) activity and concentration after single
aerobic exercise sessions conducted before and after 6 weeks of niacin therapy in men with metabolic
syndrome (MetS). Twelve men with MetS expended 500 kcal by walking at 65% of VO2max before and after
a 6-week regimen of niacin. Niacin doses were titrated by 500 mg/week from 500 to 1500 mg/day and
maintained at 1500 mg/day for the last 4 weeks. Fasting blood samples were collected before and 24
hours after each exercise session and analyzed for PON1 activity, PON1 concentration, myeloperoxidase
(MPO), apolipoprotein A1, oxidized low-density lipoprotein (oLDL), lipoprotein particle sizes and
concentrations. PON1 activity, PON1 concentration, MPO, and oLDL were unaltered following the
independent effects of exercise and niacin (P> 0.05 for all). High-density lipoprotein particle size
decreased by 3% (P= 0.040) and concentrations of small very low-density lipoprotein increased (P=
0.016) following exercise. PON1 activity increased 6.1% (P= 0.037) and PON1 concentrations increased
11.3% (P= 0.015) with the combination of exercise and niacin. Exercise and niacin works synergistically
to increase PON1 activity and concentration with little or no changes in lipoproteins or markers of lipid
oxidation.
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Introduction
The metabolic syndrome (MetS) is characterized by a
cluster of cardiovascular disease (CVD) risk factors
that include abdominal obesity, dyslipidemia, hyper-
tension, insulin resistance, and prothrombotic and
proinflammatory states.1 An individual may be classi-
fied with MetS if they have three of the following risk
factors: increased waist circumference; high triglycer-
ides (TGs); low high-density lipoprotein cholesterol
(HDLc); hypertension; and impaired fasting
glucose.1 It has been estimated that one out of three
US adults over the age of 20 can be classified as
having MetS.2
Oxidative stress may play an important role in the
development of CVD in individuals with MetS.3
HDL particles protect low-density lipoprotein (LDL)
against oxidative stress in peripheral tissues.4
However, oxidation of LDL and HDL can be attenu-
ated by an important enzyme, paraoxonase 1
(PON1).5,6 PON1 may help to prevent or slow the
atherosclerotic process by reducing the formation of
oxidized LDL (oLDL) and decreasing the uptake of
oLDL by macrophages.7 Thus, PON1 helps to
prevent the inflammatory process and oxidative
stress involved in atherosclerosis.7,8 PON1 is
synthesized and secreted by the liver and circulates
exclusively with the HDL particle.8,9 More recently,
studies have focused primarily on PON1’s antioxida-
tive properties, which are inversely related to CVD.10
Health benefits of regular exercise include decreased
blood pressure (BP), improved insulin sensitivity,
improved glucose regulation, decreased body weight,
and improved lipid profile.11 Aerobic exercise
improves the lipid profile by increasing plasma
HDLc and lowering plasma TG levels.12,13
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Sedentary individuals participating in acute aerobic
exercise at an intensity of 70–80% maximal oxygen
uptake (VO2max) and a caloric expenditure between
350 and 500 kcal have improved lipid profiles by
increasing plasma HDLc and decreasing TG concen-
trations.12,14 Acute bouts of exercise have been
reported to transiently increase PON1 activity.15,16
The means by which exercise increases PON1 activity
remains largely unknown; however, the increase in
oLDL and ROS following exercise are likely to play
roles in post-exercise PON1 changes.17 The initial pro-
tective action of PON1 to prevent oxidation of lipids is
rapidly followed by inactivation.18 The interaction
between ROS and the free sulfhydryl group at
cysteine-284 in the PON1 structure are thought to
inactivate the arylesterase activity of PON1 following
oxidative stress.18,19
Niacin is an essential B vitamin (B3) that has lipid-
lowering effects when used in prescription doses.20,21
Niacin reduces TG concentrations up to 30% and
may increase HDLc by 25%.20,21 Niacin increases
the production of apolipoprotein A1 (Apo A1) and
Apo A1 is integral for the activity of PON1.22,23
Moreover, niacin has demonstrated anti-inflammatory
properties and has been shown to reduce vascular oxi-
dative stress.24 It is possible that attenuated vascular
oxidative stress with niacin therapy is partially due to
enhanced HDL antioxidant activity mediated by
PON1.
The purpose of this investigation was to determine
the independent and combined effects of exercise and
extended-release niacin on the concentration and
activity of PON1 in men with MetS.
Subjects and methods
Participants
Twelve obese male participants, meeting the NCEP-
ATP III criteria for MetS, completed a single session
of exercise on a treadmill at 60–70% of VO2max to
expend 500 kcal. Participants who met the following
criteria were included in the study: sedentary, non-
smoking males between the ages of 30 and 65, obese
(body mass index (BMI)≥ 30 kg/m), hypertriglyceri-
demic (TG≥ 150 mg/dl), and no contraindications
to aspirin and niacin therapy. A fasting blood
sample was obtained prior to exercise and 24 hours
after exercise. Next, extended-release niacin was
physician-prescribed and participants completed 6
weeks of niacin therapy. Following the niacin interven-
tion, all participants returned to complete a single
session of exercise and blood sampling as before.
Diet and physical activity records were self-reported
during the blood sampling period.25
This study was approved by our university’s
Institutional Review Board for research involving
human subjects. All participants were fully informed
regarding all aspects of the study and provided volun-
tary written consent. The methods used for recruitment
and screening participants are published elsewhere.25
Exercise intervention
Participants completed a single session of laboratory-
based treadmill walking 1 week following a maximal
graded exercise to expend 500 kcal at 60–70%
VO2max. The caloric expenditure was estimated by
measuring expired gas (oxygen and carbon dioxide)
fractions sampled at the mouth using a pneumotach,
and breath-by-breath gas analysis system (Medical
Graphics, St Paul, MN, USA).
Extended-release niacin administration
Participants were prescribed extended-release niacin
by a physician. The extended-release niacin was
titrated from 500 to 1500 mg/day over a 3-week
period. Participants were asked to begin taking
500 mg/day right before bed for the first week.
Dosage increased to 1000 mg/day for the second
week. Dosage was increased to 1500 mg/day from
week 3 to the end of the study (week 6). Participants
were asked to take a 300 mg aspirin per day along
with the niacin to reduce the risk of flushing.25 There
were only 2 of the original 15 participants that
reported more than one episode of flushing due to
the niacin therapy.
Blood sampling
Blood samples were drawn 10–12 hours following an
overnight fast. Blood samples were drawn prior to
the exercise session and 24 hours post-exercise and
these two were repeated following 6 weeks of niacin
therapy. Blood samples were centrifuged at 3000 rpm
for 15 minutes. An aliquot of serum was prepared
and placed into a −80°C ultralow freezer until testing.
Biochemical analysis
PON1 activity
PON1 activity (arylesterase) was determined by using
a commercially available enzymatic kit (Catalog#
0801199, ZeptoMetrix Corporation; Buffalo, NY,
USA). The samples and standards were analyzed in
duplicate. The absorbance was measured at 270 nm
using a Spectronic UV1 spectrophotometer by
Thermo Scientific. The PON1 activity was reported
in kU/l. The inter-assay and intra-assay variation
was 2.94 and 2.53%, respectively.
Enzyme-linked immunosorbent assay
PON1 concentration, Apo A1, oLDL, and myeloper-
oxidase (MPO) were determined using an enzyme-
linked immunosorbent assay: (Catalog# E0243HU,
USCN Life Sciences Inc., Wuhan, China; Catalog#
EA5201-1, AssayPro LLC., St Charles, MO, USA;
Catalog# BI20042, ALPCO Diagnostics, Salem, NH,
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USA; and Catalog# K6631A, ALPCO Diagnostics).
The samples and standards were analyzed in duplicate.
A 96 well-plate washer and plate reader (Biotek
Instruments Inc.; Winooski, VT, USA) was used and
programmed according to manufacturer’s instructions.
The inter-assay for each assay was <4.88, 4.94, 4.11,
and 3.65%, respectively. The intra-assay variation for
each was <4.55, 5.01, 4.96, and 4.34%, respectively.
Lipoprotein particle size
Frozen serum samples were sent to Liposcience Inc. for
nuclear magnetic resonance spectroscopy testing. Very
LDL (VLDL), LDL, and HDL particle numbers and
sizes were determined by nuclear magnetic resonance
(NMR; Liposcience Inc., Raleigh, NC, USA).26,27
The coefficient of variation (CV) for particle numbers
was <4%. The CV for particle sizes was <2%.
Statistical analysis
Group means and standard deviations were deter-
mined for the following descriptive statistics: age
(years); height (cm); weight (kg); BMI (kg/m); waist
hip ratio; VO2max (ml/kg/minute). The dependent
variables of interest are PON1 concentration, PON1
activity, MPO, Apo A1, oLDL, and lipoprotein par-
ticle size and number for HDL and LDL. The
Shapiro–Wilks test for normality was used to
determine if the baseline variables of interests were
normally distributed. A multiple 1 group (group) × 4
(sampling point) repeated measures analysis of var-
iance was used to determine significant changes in
variables of interest. A comparison-wise alpha level
was set at P< 0.05. Duncan’s NMR tests were used
to follow-up the global tests. Pearson product-
moment correlations were determined to characterize
relationships between baseline concentrations and
changes in variables of interest.
Results
Participants
The baseline physiological characteristics are provided
in Table 1. The participant’s baseline variables are
presented in Table 2. All participates maintained
their body weight throughout the study.25
PON1 response to exercise
Exercise decreased TG concentrations (P= 0.006) and
reduced HDL particle size (P= 0.040). Furthermore,
the session of exercise resulted in a significantly
reduced ratio of TG: HDLc (P< 0.001). However,
PON1 concentration, PON1 activity, oLDL,
MPO, and all other lipoprotein particle sizes and concen-
trations remained unchanged with exercise (Table 2).
At baseline, PON1 concentration was correlated
with Apo A1 (P= 0.041). Changes in dependent vari-
ables that occurred with exercise were computed
(Change= 24 hours post-exercise − baseline) and
relationships among these change variables were
explored. The exercise-induced change in PON1
activity was significantly correlated with exercise-
induced changes in HDLc (r= 0.740, P= 0.006). No
other correlations between PON1 concentration,
PON1 activity, TG: HDLc ratio, and lipoprotein
characteristics were observed.
Six weeks of niacin therapy
Six weeks of niacin therapy did not alter PON1
activity (P= 0.143), PON1 concentration P= 0.536),
or Apo A1 (P= 0.198). Six weeks of niacin signifi-
cantly reduced TG (P< 0.001) and medium small
LDL particle concentration (P= 0.018). Six weeks of
niacin therapy significantly reduced the ratio of TG:
HDL (P< 0.001). However, no other lipid lipoprotein
changes were observed with niacin (see Table 3).
Changes in dependent variables of interest occurring
with niacin therapy (Change= values obtained after 6
weeks of niacin therapy − values obtained at baseline)
were calculated and the relationships between baseline
PON1 activity and concentration and change variables
were determined. Niacin-induced changes in PON1
concentration were significantly correlated with
changes in LDL particle number (r= 0.775, P=
0.005) and changes in small LDL particle numbers
(r= 0.878, P< 0.001). Niacin-induced changes in
Table 1 Baseline physiological characteristics (means± SEM)
Variable Units Mean± SEM Minimum Maximum
Age years 44±2 37 51
Height cm 175.6±2.8 165.5 185.7
Body weight kg 106.9±5.1 88.4 125.4
BMI kg/m2 34.5±0.9 31.1 37.9
Waist circumference cm 108.8±8.2 100.6 117.0
% Fat % of body weight 35±1 30 40
VO2max ml/minute/kg 27.5±1.6 21.9 33.1
Glucose mmol/l 5.99±0.28 3.83 8.16
NEFA mmol/l 0.49±0.03 0.39 0.59
HDLc mmol/l 1.06±0.05 0.70 1.35
Triglyceride mmol/l 3.31±0.32 2.01 5.13
BMI, body mass index; NEFA, non-esterified fatty acids; VO2max, maximal oxygen consumption; HDLc, high-density lipoprotein
cholesterol. Table modified from Plaisance et al.25
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PON1 status were not correlated with niacin-induced
changes in the ratio of TG: HDLc.
Combined effects of exercise and niacin therapy
PON1 concentration and PON1 activity responses to
the combined effects of acute exercise and 6 weeks of
extended-release niacin therapy are presented in
Fig. 1A and B. PON1 concentration was significantly
increased (P= 0.015) (Fig. 1A). PON1 activity was
significantly increased following the combined effects
of acute exercise and extended-release niacin (P=
0.037) (Fig. 1B). TG were significantly reduced
Table 2 Response to exercise (means± SEM)
Variable Units Baseline 24 hours post-exercise P value
PON1a kU/l 125.9±4.9 131.5±4.0 0.269
PON1c μg/ml 112.4±8.2 118.9±8.5 0.391
Apo A1 mmol/l 28.0±9.1 28.1±7.4 0.983
Total HDL particles μmol/l 31.5±1.3 32.1±1.7 0.469
Large HDL particles μmol/l 3.5±0.5 3.1±0.5 0.068
Medium HDL particles μmol/l 5.1±1.5 4.2±1.3 0.496
Small HDL particles μmol/l 22.9±1.4 24.9±1.5 0.214
HDL particle size nm 8.6±0.1 8.5±0.1 0.040*
HDLc mmol/l 1.06±0.05 1.04±0.05 0.403
TG mmol/l 3.31±0.32 2.61±0.32 0.006*
TG: HDLc ratio 3.12±0.12 2.51±0.08 <0.001*
Large VLDL particles nmol/l 5.7±1.0 5.5±1.0 0.321
Medium VLDL particles nmol/l 31.5±5.3 28.2±3.9 0.222
Small VLDL particles nmol/l 48.6±3.8 56.0±4.9 0.016*
VLDL particle size nm 58.4±2.4 56.4±2.1 0.102
Total LDL particles nmol/l 1788.3±105.1 1829.2±111.3 0.272
Intermediate LDL particles nmol/l 43.6±13.1 49.8±9.7 0.581
Large LDL particles nmol/l 264.7±47.5 273.0±47.0 0.722
Small LDL particles nmol/l 1480.0±111.2 1506.3±107.5 0.534
Medium small LDL particles nmol/l 312.4±25.0 307.7±24.2 0.755
Very small LDL particles nmol/l 1167.6±86.9 1198.4±85.3 0.355
LDL particle size nm 20.1±0.1 20.1±0.1 0.385
oLDL mmol/l 8.2±0.5 6.9±2.6 0.490
Baseline, before exercise (control); 24 hours post-exercise; PON1a, paraoxonase 1 activity; PON1c, paraoxonase 1 concentration;
Apo A1, apolipoprotein A1; HDL, high-density lipoprotein; HDLc, high-density lipoprotein cholesterol; TG, triglyericide concentration.
VLDL, very low-density lipoprotein; LDL, low-density lipoprotein, oLDL, oxidized low-density lipoprotein.
Significance compared to baseline (control): *P< 0.05.
Table 3 Effects of niacin alone and niacin+ exercise (means± SEM)
Variable Units Baseline 6 weeks of niacin 6 weeks of niacin+ 1 exercise session
PON1a kU/l 125.9±4.9 115.9±6.2 122.9±5.5‡
PON1c μg/ml 112.4±8.2 105.9±8.5 121.9±9.3‡
Apo A1 mmol/l 28.0±9.1 24.1±5.9 21.5±15.8
Total HDL particles μmol/l 31.5±1.3 32.0±1.1 33.2±1.3
Large HDL particles μmol/l 3.5±0.5 3.8±0.8 3.8±0.6
Medium HDL particles μmol/l 5.1±1.5 2.9±0.9 3.9±0.7
Small HDL particles μmol/l 22.9±1.4 25.3±1.1 25.5±1.4
HDL particle size nm 8.6±0.1 8.6±0.1 8.6±0.1
HDLc mmol/l 1.06±0.05 1.06±0.05 1.11±0.05
TG mmol/l 3.31±0.32 2.21±0.21† 1.80±0.14‡
TG: HDLc ratio 3.12±0.12 2.08±0.05† 1.62±0.04‡
Large VLDL particles nmol/l 5.7±1.0 5.4±0.8 4.2±1.0‡
Medium VLDL particles nmol/l 31.5±5.3 25.4±3.7 25.9±4.0
Small VLDL particles nmol/l 48.6±3.8 44.6±5.8 49.4±4.8
VLDL particle size nm 58.4±2.4 59.9±3.0 55.5±2.9‡
Total LDL particles nmol/l 1788.3±105.1 1626.1±131.6 1678.0±121.1
Intermediate LDL particles nmol/l 43.6±13.1 32.1±13.7 38.9±12.8
Large LDL particles nmol/l 264.7±47.5 349.4±65.7 352.1±51.8
Small LDL particles nmol/l 1480.0±111.2 1244.6±128.8 1287.4±110.1
Medium small LDL particles nmol/l 312.4±25.0 244.6±26.3† 266.4±24.7
Very small LDL particles nmol/l 1167.6±86.9 1000.0±103.5 1021.1±86.3
LDL particle size nm 20.1±0.1 20.3±0.2 20.4±0.1
oLDL mmol/l 8.2±0.5 5.9±2.0 8.11±2.51
Baseline, before exercise (control); Niacin baseline, 6 weeks of niacin before exercise; PON1a, paraoxonase 1 activity; PON1c,
paraoxonase 1 concentration; Apo A1, apolipoprotein A1; HDL, high-density lipoprotein; HDLc, high-density lipoprotein cholesterol;
TG, triglyericide concentration; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; oLDL, oxidized low-density
lipoprotein concentration.
Significance compared to baseline, †P< 0.05; significance compared to niacin baseline, ‡P< 0.05.
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following the combined effects of exercise and niacin
therapy (P= 0.006). Exercise and niacin therapy
resulted in a significantly lower ratio of TG: HDLc
as compared to niacin alone (P< 0.001). Likewise,
the combined effects of acute exercise and extended-
release niacin significantly reduced large VLDL par-
ticle numbers (P= 0.043). All other lipoprotein
changes were observed (see Table 3).
Changes in dependent variables of interest occur-
ring with exercise and niacin therapy (Change=
values obtained following 6 weeks of niacin therapy
plus exercise− values obtained at baseline following
niacin therapy alone) were calculated and the relation-
ships between baseline PON1 activity and concen-
tration and change variables were determined.
Exercise and niacin-induced changes in PON1
activity were correlated with changes in HDL particle
size (r=−0.627, P= 0.039). Changes in PON1 con-
centration was not correlated with any change variable
following the combined effects of exercise and niacin
therapy.
Discussion
The primary and novel findings of this study are that
exercise and niacin together increased PON1 concen-
tration and activity, but PON1 characteristics were not
altered by either intervention alone. Our results indicate
for the first time that these therapeutic interventions
have additive or complementary effects on PON1 con-
centration and activity in those withmetabolic dyslipide-
mia. Furthermore, PON1 concentration and activity
can be elevated in the absence of changes in markers
of oxidative stress and changes in lipoprotein lipids
that are often reported with either exercise or niacin.
Dynamic continuous exercise has been previously
shown to increase PON1 activity15,16 with some excep-
tions.28,29 The exercise effects on PON1 activity
appear to be transient as we and others do not
observe significant elevations 24 hours after complet-
ing exercise.15,16,29 Tomas et al.15 found that PON1
activity and oLDL were significantly increased follow-
ing 30 minutes of cycle ergometry in previously seden-
tary individuals who completed 16 weeks of aerobic
exercise training. The post-training results of the exer-
cise session were different from what was observed
prior to training. It may be argued, based on the find-
ings of Tomas et al.,15 that long-term exercise training
may be necessary for PON1 changes to take place. In
other words, systemic, cellular, and molecular changes
induced by regular practiced exercise may be necessary
for increasing PON1. Limited support for this position
may be found from cross-sectional results where ado-
lescents that participated in sports had a higher
PON1 activity than their sedentary counterparts.30,31
In our study, the independent effects of exercise did
not alter PON1 concentration or activity.
Increases in HDLc and decreases in TG are
common following a single session of exercise at inten-
sities between 70 and 80% while expending
300–500 kcal. These changes are maintained up to
48 hours post-exercise.12–14 However, HDLc was not
altered in this current investigation.
Exercise resulted in smaller HDL particles without
changes in Apo A1 or LDL characteristics and in
the absence of changes in PON1 concentration or
activity. In addition, PON1 concentration and activity
were not correlated with exercise-induced changes in
HDL particle size. Our findings may be interpreted
to mean that the reduction in HDL particle size does
not necessarily result in characteristic changes in
PON1 activity. Our results are in conflict with those
of Bergmeier et al.32 that provide evidence that a
reduction in HDL particle size contributes to sub-
sequent increases in PON1 concentration and activity.
To our knowledge, ours is the first study designed to
examine PON1 changes with niacin therapy. Our
results indicate that niacin doses up to 1500 mg/day
for 6 weeks does not appear to affect PON1, HDL,
Apo A1, or blood markers of lipid peroxidation.
Niacin has been used as an effective therapy for
increasing HDLc and lowering TG concen-
trations.20,21,33 Our results are consistent with those
published previously regarding the TG-lowering
effects of niacin.20,21,33 We found that HDL particle
sizes, HDL particle numbers, and HDLc were not
altered in our investigation. There are several groups
Figure 1 PON1 concentration and activity response to exercise and niacin therapy, means± SD. (A) PON1 concentration is
presented in micrograms per milliliter of sample; Baseline (control), before exercise; Exercise, 24 hours post-exercise; Niacin
Baseline, 6 weeks of niacin therapy; Niacin+ Exercise, 24 hours post-exercise plus niacin. (B) PON1 activity is presented in kU/l,
kilo international units per liter of sample; significance between niacin baseline and niacin+ exercise, *P< 0.05.
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that have examined particle size distribution following
niacin therapy.34–36 In contrast, several investigators
reported significant increases in large HDL particle
numbers and significant decreases in small HDL par-
ticle numbers following 12–16 weeks of niacin therapy
with dosages ranging from 1000 to 2000 mg/day in indi-
viduals with coronary artery disease and MetS.34–36
Niacin increases the production of Apo A1 as com-
pared to placebo.23 Apo A1 plays a vital role at increas-
ing the activity of PON1.22 Lamon-Fava et al.23 found
that extended-release niacin titrated over 12 weeks at a
dosage of 2000 mg/day would cause a significant
increase in Apo A1. However, in our current investi-
gation, Apo A1 was not altered following 6 weeks of
niacin therapy at a dosage of 1500 mg/day.
MPO is a byproduct of lipoprotein lipid oxidation,
and MPO may reduce the protective effects of HDL
to maintain vascular function of the endothelium.24
On the other hand, niacin is thought to improve vascu-
lar health by reducing oxidative stress.24 Sorrentino
et al.24 found a significant reduction in MPO following
12 weeks of niacin therapy titrated to 1500 mg/day in
individuals with type 2 diabetes mellitus and meeting
criteria for MetS. MPO was not altered following 6
weeks of niacin therapy in the present study.
Although, extended-release niacin therapy reduced
total and small LDL particle numbers by 10–18%
and increased large LDL particles by 32% in our
study, these changes were not significant. Kuvin
et al.34 found that extended-release niacin significantly
reduced small LDL particles by 12% and significantly
increased large LDL particles by 82%. We did not
observe changes in PON1 concentration or activity,
but changes in lipoprotein metabolism, decreased
TG and decreased LDL particle distribution, are con-
sistent with previously reported changes with niacin.
The reduction in small LDL particles and the increase
in the large LDL particles are consistent with a shift
towards a less atherogenic LDL profile following 6
weeks of niacin therapy.
Finally, it is possible that the dual interventions of
exercise and niacin therapy complement one another
to increase PON1 concentration and activity because
we observed significant increases in both after combin-
ing these strategies. Interestingly, transient changes
were observed 24 hours after exercise. This has not
been observed in previous studies. These statistically sig-
nificant changes in PON1 that we reported may or may
not have clinical or physiological significance. We inter-
pret this to mean that niacin exerts an influence on exer-
cise response that persists beyond what has been shown
for exercise alone. However, these postulated mechan-
isms have yet to be confirmed by experimental data.
The combination of exercise and niacin therapy on
lipoprotein particle size distribution has not been
studied. Large VLDL particle size are considered to
be a major contributor to abnormal lipoprotein metab-
olism.37 The combination of exercise and extended-
release niacin therapy significantly decreased VLDL
particle numbers by 8%. The greatest change was
found with VLDL particle size, which decreased by
28% following the dual intervention. Independently,
exercise and niacin have been shown to decrease the
availability of hepatic TG to incorporate into VLDL
and results in a reduction of VLDL particle size.37
The results from these studies may help us understand
how exercise and niacin work together. Our results
suggest that exercise and niacin appear to have a comp-
lementary effect on VLDL particle distribution.
Several limitations of this current study must be con-
sidered. First, this study only included obese male par-
ticipants that were not on lipid altering or BP
medications, non-smokers, or sedentary. Second, the
sample size was small and included only one exercise
session before and after 6 weeks of niacin. Third,
PON1 status may be affected by a variety of factors,
which include pharmacological agents, physical
activity, smoking, and diet. Fourth, we did not pheno-
type or look at PON1-192 and PON1-55 polymorph-
isms. Fifth, the participants were asked to self-report
physical activity and dietary logs for 3 days prior to
the investigation. Finally, our intent was to observe
changes in PON1 using a physiological hypothesis
but nothing to address mechanisms.
In conclusion, PON1 concentration and/or activity
may be important and often overlooked characteristics
of HDL to decrease an individual’s risk for CVD
either through lifestyle modification or through
pharmacological intervention. The independent
actions of exercise did not alter PON1 concentration
and activity. Similarly, 6 weeks of extended-release
niacin therapy did not alter PON1 concentration and
activity. However, when exercise was completed after
6 weeks of extended-release niacin therapy, PON1 con-
centration and activity significantly increased without
observed changes in oLDL and MPO. Our findings
may suggest that several factors are working together
to elicit changes in PON1 following exercise and
niacin therapy. Therefore, additional research is
needed to investigate the potential mechanisms
responsible to increase PON1.
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